文献速递青光眼

胰高血糖素样肽-1受体激动剂与2型糖尿病患者青光眼风险的关联

Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes.
PubMed 文献 · Ophthalmology · 2024-03-13

这项全国性嵌套病例对照研究纳入264708例2型糖尿病患者,识别1737例新发青光眼病例并按出生年份、性别和第二线治疗开始日期匹配8685例无青光眼对照。与接受其他二线降糖药者相比,暴露于GLP-1RA者青光眼风险较低(HR 0.81,95%CI 0.70-0.94,P=0.006),治疗超过3年风险进一步降低(HR 0.71,95%CI 0.55-0.91,P=0.007)。

要点

  • GLP-1RA暴露与青光眼风险降低相关(HR 0.81,95%CI 0.70-0.94,P=0.006)。
  • 治疗超过3年者风险进一步降低(HR 0.71,95%CI 0.55-0.91,P=0.007)。
  • 治疗0至1年和1至3年未达统计学显著(HR 0.89和0.85,95%CI均跨1)。

核心结论

  • 与接受其他二线降糖药相比,暴露于GLP-1RA与青光眼发生风险较低相关。

研究设计与样本

  • 全国性嵌套病例对照研究,从264708例队列中识别1737例新发青光眼病例,按出生年份、性别和第二线治疗开始日期以1:5匹配8685例无青光眼对照,所有对象年龄大于21岁、接受二甲双胍加第二种降糖药治疗、无青光眼史、眼外伤史或眼手术史。

主要发现

  • 与未接受GLP-1RA治疗的参照组相比,暴露于GLP-1RA者新发青光眼风险较低(HR 0.81,95%CI 0.70-0.94,P=0.006)。
  • 治疗超过3年者风险进一步降低(HR 0.71,95%CI 0.55-0.91,P=0.007)。
  • 治疗0至1年(HR 0.89,95%CI 0.70-1.14,P=0.35)和1至3年(HR 0.85,95%CI 0.67-1.06,P=0.15)未达统计学显著。

关键数值与推荐

  • 青光眼定义为首诊诊断、首次使用青光眼特异性药物或首次青光眼特异性手术干预。
  • 采用条件logistic回归计算调整后风险比(HR)及95%置信区间(CI)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and the development of glaucoma in individuals with type 2 diabetes. DESIGN: Nationwide, nested case-control study. PARTICIPANTS: From a nationwide cohort of 264 708 individuals, we identified 1737 incident glaucoma cases and matched them to 8685 glaucoma-free controls, all aged more than 21 years and treated with metformin and a second-line antihyperglycemic drug formulation, with no history of glaucoma, eye trauma, or eye surgery. METHODS: Cases were incidence-density-matched to 5 controls by birth year, sex, and date of second-line treatment initiation. MAIN OUTCOME MEASURES: Conditional logistic regression was used to calculate adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for glaucoma, defined by first-time diagnosis, first-time use of glaucoma-specific medication, or first-time glaucoma-specific surgical intervention. RESULTS: Compared with the reference group, who received treatments other than GLP-1RA, individuals who were exposed to GLP-1RA treatment exhibited a lower risk of incident glaucoma (HR, 0.81; CI, 0.70-0.94; P = 0.006). Prolonged treatment extending beyond 3 years lowered the risk even further (HR, 0.71; CI, 0.55-0.91; P = 0.007). Treatment with GLP-1RA for 0 to 1 year (HR, 0.89; CI, 0.70-1.14; P = 0.35) and 1 to 3 years (HR, 0.85; CI, 0.67-1.06; P = 0.15) was not significant. CONCLUSIONS: Exposure to GLP-1RA was associated with a lower risk of developing glaucoma compared with receiving other second-line antihyperglycemic medication. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Niazi S, Gnesin F, Thein AS, et al. Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes. Ophthalmology. 2024. PMID: 38490274. doi:10.1016/j.ophtha.2024.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。